BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fatourou EM, Koskinas JS. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. Expert Review of Anticancer Therapy 2014;9:1499-510. [DOI: 10.1586/era.09.103] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Wu H, Chen B, Peng B. Effects of intratumoral injection of immunoactivator after microwave ablation on antitumor immunity in a mouse model of hepatocellular carcinoma. Exp Ther Med 2018;15:1914-7. [PMID: 29434784 DOI: 10.3892/etm.2017.5633] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Shen S, Peng H, Wang Y, Xu M, Lin M, Xie X, Peng B, Kuang M. Screening for immune-potentiating antigens from hepatocellular carcinoma patients after radiofrequency ablation by serum proteomic analysis. BMC Cancer 2018;18:117. [PMID: 29386009 DOI: 10.1186/s12885-018-4011-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
3 Fatourou EM, Tsochatzis EA. ART and science in using transarterial chemoembolization for retreating patients with hepatocellular carcinoma. Hepatobiliary Surg Nutr 2014;3:415-8. [PMID: 25568865 DOI: 10.3978/j.issn.2304-3881.2014.07.01] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
4 Takaba H, Morishita Y, Tomofuji Y, Danks L, Nitta T, Komatsu N, Kodama T, Takayanagi H. Fezf2 Orchestrates a Thymic Program of Self-Antigen Expression for Immune Tolerance. Cell 2015;163:975-87. [PMID: 26544942 DOI: 10.1016/j.cell.2015.10.013] [Cited by in Crossref: 191] [Cited by in F6Publishing: 171] [Article Influence: 31.8] [Reference Citation Analysis]
5 Tsochatzis EA, Fatourou EM, Triantos CK, Burroughs AK. Transarterial therapies for hepatocellular carcinoma. Recent Results Cancer Res 2013;190:195-206. [PMID: 22941022 DOI: 10.1007/978-3-642-16037-0_13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
6 Wang XD, Wang L, Ji FJ, Zhu JM, Ayana DA, Fang XD. Decreased CD27 on B lymphocytes in patients with primary hepatocellular carcinoma. J Int Med Res. 2012;40:307-316. [PMID: 22429370 DOI: 10.1177/147323001204000131] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
7 Tsochatzis EA, Germani G, Burroughs AK. Transarterial Chemoembolization, Transarterial Chemotherapy, and Intra-arterial Chemotherapy for Hepatocellular Carcinoma Treatment. Seminars in Oncology 2010;37:89-93. [DOI: 10.1053/j.seminoncol.2010.03.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
8 Yoo J, Lee JM. Diagnostic Value of High Frame Rate Contrast-enhanced Ultrasonography and Post-processing Contrast Vector Imaging for Evaluation of Focal Liver Lesions: A Feasibility Study. Ultrasound Med Biol 2020;46:2254-64. [PMID: 32546409 DOI: 10.1016/j.ultrasmedbio.2020.05.001] [Reference Citation Analysis]
9 Abi-Jaoudeh N, Duffy AG, Greten TF, Kohn EC, Clark TW, Wood BJ. Personalized oncology in interventional radiology. J Vasc Interv Radiol 2013;24:1083-92; quiz 1093. [PMID: 23885909 DOI: 10.1016/j.jvir.2013.04.019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
10 Zhao GS, Liu Y, Zhang Q, Li C, Zhang YW, Ren ZZ, Zhou J, Zhang M. Transarterial chemoembolization combined with Huaier granule for the treatment of primary hepatic carcinoma: Safety and efficacy. Medicine (Baltimore) 2017;96:e7589. [PMID: 28723799 DOI: 10.1097/MD.0000000000007589] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
11 Mondelli MU. NKG2D and its ligands: key to immunotherapy of liver cancer? J Hepatol 2012;56:308-10. [PMID: 21798219 DOI: 10.1016/j.jhep.2011.07.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
12 Park KH, Kwon SH, Lee YS, Jeong SW, Jang JY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim YJ. Predictive factors of contrast-enhanced ultrasonography for the response to transarterial chemoembolization in hepatocellular carcinoma. Clin Mol Hepatol 2015;21:158-64. [PMID: 26157753 DOI: 10.3350/cmh.2015.21.2.158] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
13 Tsochatzis EA, Fatourou E, O’Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol 2014; 20(12): 3069-3077 [PMID: 24695579 DOI: 10.3748/wjg.v20.i12.3069] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
14 Chen J, Yang L, Chen H, Yuan T, Liu M, Chen P. Recombinant adenovirus encoding FAT10 small interfering RNA inhibits HCC growth in vitro and in vivo. Experimental and Molecular Pathology 2014;96:207-11. [DOI: 10.1016/j.yexmp.2014.01.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
15 Jiang L, Xu J, Ni J, Gao X, Zhu Z, Dong D, Wang X, Shi C, Tao X, Dong W, Gao Y. A functional insertion/deletion polymorphism in the proximal promoter of CD3G is associated with susceptibility for hepatocellular carcinoma in Chinese population. DNA Cell Biol 2012;31:1480-5. [PMID: 22731821 DOI: 10.1089/dna.2012.1706] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
16 Hetta HF, Zahran AM, Mansor SG, Abdel-Malek MO, Mekky MA, Abbas WA. Frequency and Implications of myeloid-derived suppressor cells and lymphocyte subsets in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. J Med Virol 2019;91:1319-28. [PMID: 30761547 DOI: 10.1002/jmv.25428] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
17 Cui J, Wang N, Zhao H, Jin H, Wang G, Niu C, Terunuma H, He H, Li W. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer. 2014;134:342-351. [PMID: 23825037 DOI: 10.1002/ijc.28372] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 6.3] [Reference Citation Analysis]
18 Luo C, Shibata K, Suzuki S, Kajiyama H, Senga T, Koya Y, Daimon M, Yamashita M, Kikkawa F. GPC3 expression in mouse ovarian cancer induces GPC3‑specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth. Oncol Rep 2014;32:913-21. [PMID: 24992906 DOI: 10.3892/or.2014.3300] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]